GLP1+GIP 10 mg vial

Tirzepatide 10 mg - mechanism of action and metabolic significance

Tirzepatide 10 mg is a synthetic peptide analog designed as a dual agonist of GIPR and GLP-1R receptors, which belong to the G protein-coupled receptor (GPCR) family.

In research models, activation of these receptors leads to:

• Increasing intracellular cAMP concentration,
• Increased glucose-dependent insulinotropic response,
• modulation of glucagon secretion,
• Effect on the rate of gastric emptying,
• impacts on central mechanisms regulating appetite.

Dual activation of the GIP/GLP-1 axis is interpreted in the literature as a synergistic effect, integrating glycemic control and energy balance regulation.

Effects on body weight parameters in clinical trials

The SURMOUNT-1 study program (72 weeks of follow-up) reported an average weight reduction of about 19-20% at the 10 mg dose.

Parallel observations were made:

• Improving indicators of insulin resistance,
• favorable changes in lipidogram,
• waist circumference reduction,
• Stabilization of glycemic parameters.

Comparative analyses showed greater reductions in HbA1c and body weight than with selective GLP-1 agonism.

Pharmacodynamic profile

The 10-mg dose provides an important benchmark in dose-effect analyses, allowing assessment of the intensity of metabolic response and tolerance under controlled study conditions.

In clinical trials, the most commonly reported side effects were gastrointestinal and dose-dependent.

Nature of the product

Tirzepatide 10 mg offered in the laboratory market is a reference material for research on:

• incretin receptor signaling,

• Glucose and lipid metabolism,

• Energy balance regulation,

• GPCR mechanisms.

The product is intended for research use only (Research Use Only).

Tirzepatide 10 mg online availability and where to buy information

• Tirzepatide 10 mg is available by prescription only In stationary pharmacies and online pharmacies that have legal sales of prescription drugs.

•  Tirzepatide is also available needs scientific research and laboratory use. It is not intended for self-medication or home use

• In some countries, access to the product may be regulated through reimbursable drug lists or the requirement for prior therapy with other methods (diet, physical activity).

Tirzepatide 10 mg comparison with other peptides

• Semaglutide: acts only on GLP-1 receptor, efficacy in weight loss average ~15%, used in type 2 diabetes and obesity therapy.

• Tirzepatide: dual mechanism (GLP-1 + GIP), efficacy in weight loss ~20-25%, plus better glycemic control.

• Retatrutide: experimental triple peptide (GLP-1 + GIP + glucagon receptor), preliminary studies suggest very high weight reduction, still in clinical trial phase.

Tirzepatide 10 mg is distinguished by the fact that it combines Highly effective weight reduction with glycemic control and is available in weekly doses, making it more convenient to use compared to other peptides.

Research and Sources:

Efficacy and safety of a novel dual GIP and GLP-1 receptor

Thirzepatide, a dual GIP/GLP-1 receptor

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.